Showing 4,561 - 4,580 results of 47,671 for search '"reporter"', query time: 0.12s Refine Results
  1. 4561
  2. 4562

    Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System by Lingqing Ding, Congqin Chen, Yongkuan Yang, Jie Fang, Longxing Cao, Yige Liu

    Published 2022-01-01
    “…The reporting odds ratio (ROR) with relevant 95% confidence interval (95% CI) was calculated as the index of disproportionality. …”
    Get full text
    Article
  3. 4563
  4. 4564
  5. 4565
  6. 4566
  7. 4567
  8. 4568
  9. 4569
  10. 4570

    G.F. Dormidontov's report on A.A. Simolin's doctoral dissertation 'Influence of the Moment of Gratuitousness in Civil Law' by K.M. Arslanov

    Published 2017-04-01
    “…This is the first time when the report, which is currently stored in the National Archives of the Republic of Tatarstan (Russia), has been reproduced verbatim. …”
    Get full text
    Article
  11. 4571

    Active Liver Bleed Caught During FAST Exam from Spontaneous Hemangioma Rupture: A Case Report by Raul Rodriguez, Nicole Aviles

    Published 2025-01-01
    “…Specific solid organ injury including an active liver bleed can also be detected during FAST exam, as seen in this case of a unstable hypotensive patient. Case Report: A 55-year-old male who had recently been admitted to trauma service due to multiple rib fractures presented back to the emergency department (ED) due to an episode of syncope and was found to have an acute, left segmental pulmonary embolism. …”
    Get full text
    Article
  12. 4572
  13. 4573
  14. 4574
  15. 4575
  16. 4576

    Safety assessment of rosuvastatin-fenofibrate combination in the treatment of hyperlipidemia based on FDA’s adverse event reporting system database by Qun Li, Wenya Shan, Saiwei Wu

    Published 2025-02-01
    “…The proportional report ratio (PRR), reporting odds ratio (ROR), and Bayesian Confidence Propagation Neural Network (BCPNN) analysis were used to extract data from FAERS for suspected signals referring to the combination of rosuvastatin and fenofibrate.ResultsA total of 68 safety signals were detected from the top 250 AEs in 3,587 reports, of which 28 signals were not included in the drug labels. …”
    Get full text
    Article
  17. 4577

    Safety profiles of IDH inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database by Ximu Sun, Han Zhou, Yanming Li, Yanhui Luo, Qixiang Guo, Yixin Sun, Chenguang Jia, Bin Wang, Maoquan Qin, Peng Guo

    Published 2025-02-01
    “…Only IDH inhibitors reported as the target drug and coded as the primary suspect (PS) were included in the analysis. …”
    Get full text
    Article
  18. 4578

    GELECEĞİN FİNANSAL BİLGİ PAYLAŞIM PLATFORMU: XBRL (EXTENSIBLE BUSINESS REPORTING LANGUAGE-GENİŞLETİLEBİLİR İŞLETME RAPORLAMA DİLİ) by Adnan SEVİM, Fatih TEMİZEL

    Published 2009-06-01
    “…Literatürde yer alan öneriler içinde en çok taraftar bulan XBRL (Extensible Business Reporting Language) ele alınarak finansal piyasalardaki bilgi kullanıcılarına yönelik potansiyel katkılar incelenmiştir. …”
    Get full text
    Article
  19. 4579

    Neuroplasticity and activity-based rehabilitation of a patient with post-surgical chronic Pott’s spine: a case report by Raveena Kini, Prachita Walankar, Aman Minocha, Vrushali Panhale

    Published 2025-01-01
    “…Case presentation We present a case of a 17-year-old male, with a history of Pott’s spine for 14 years. He has reported with anterior wedge compression and resorption of T7, T8, and T9 vertebral bodies along with Gibbus spine deformity and subsequent spinal cord compression. …”
    Get full text
    Article
  20. 4580

    Case report: A case of type 1 diabetes with diabetic ketoacidosis induced by envafolimab treatment in hepatocellular carcinoma by Youjia Li, Kai Qu, Xiuli Li, Xin Yang, Kanghuai Zhang, Jiao Xie

    Published 2025-01-01
    “…This case report presents a 57-year-old male with hepatocellular carcinoma who developed Type 1 Diabetes Mellitus (T1DM) and diabetic ketoacidosis (DKA) following treatment with Envafolimab, a PD-L1 immune checkpoint inhibitor. …”
    Get full text
    Article